Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Hodgkin Disease, Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Recurrence, Lymphoma, Mantle-Cell

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell, Marginal Zone

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular

Lymphoma, Follicular

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell, Marginal Zone

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Advanced Solid Tumor

Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Mantle-Cell

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell, Marginal Zone

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Lymphoma, Follicular

Waldenstrom Macroglobulinemia

Lymphoma, B-Cell, Marginal Zone

Lymphoma, Lymphoma, Follicular

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

MAHOGANY

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

OLYMPIA-5

ECLAT

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

GLOBRYTE

EPCORE™FL-2

EPCORE DLBCL-4

SYMPHONY-1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

SIDNEY

HO170DLBCL

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Pola-ZR2P in Previously Untreated DLBCL

REPIFIR

MTR²

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

V-MIND

MorningLyte

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

ZGR

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

REFRACT

Ballondor

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Genotype-guided Treatment in DLBCL